Tags

Type your tag names separated by a space and hit enter

Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study.
Menopause 2003 Mar-Apr; 10(2):147-53M

Abstract

OBJECTIVE

To investigate the efficacy of dietary soy proteins containing differing amounts of isoflavones on the number and severity of vasomotor symptoms (hot flashes and night sweats) in peri- and postmenopausal women.

DESIGN

A double-masked, randomized, controlled, clinical trial was conducted. A total of 241 community-dwelling women reporting vasomotor symptoms at baseline were randomized into one of three groups. In all groups, participants consumed a daily supplement containing 25 g of soy protein and were randomly assigned to one of three groups: (a) isoflavone extracted soy protein (control), (b) soy protein with a medium dose of isoflavones (42 mg/day), or (c) soy protein with a higher dose of isoflavones (58 mg/day). The primary outcome measure in this trial was change in reported vasomotor symptoms.

RESULTS

A reduction in the number and severity of vasomotor symptoms was observed in all three treatment groups. No significant differences in the number and severity of vasomotor symptoms were observed among the high isoflavone, middle isoflavone, or control groups. The lack of a between-treatment group effect was observed even after stratified by number of baseline symptoms and use of traditional hormone replacement therapy.

CONCLUSIONS

These data suggest that soy protein containing 42 or 58 mg of isoflavones is no more effective than isoflavone-extracted soy protein for improving the number and severity of vasomotor symptoms in peri- and postmenopausal women.

Authors+Show Affiliations

Departments of Public Health Sciences, Pathology, and Obstetrics and Gynecology, Wake Forest University School of Medicine, and Lyndhurst Gynecology Associates, Winston-Salem, NC 27157, USA. gburke@wfubmc.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12627040

Citation

Burke, Gregory L., et al. "Soy Protein and Isoflavone Effects On Vasomotor Symptoms in Peri- and Postmenopausal Women: the Soy Estrogen Alternative Study." Menopause (New York, N.Y.), vol. 10, no. 2, 2003, pp. 147-53.
Burke GL, Legault C, Anthony M, et al. Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study. Menopause. 2003;10(2):147-53.
Burke, G. L., Legault, C., Anthony, M., Bland, D. R., Morgan, T. M., Naughton, M. J., ... Vitolins, M. Z. (2003). Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study. Menopause (New York, N.Y.), 10(2), pp. 147-53.
Burke GL, et al. Soy Protein and Isoflavone Effects On Vasomotor Symptoms in Peri- and Postmenopausal Women: the Soy Estrogen Alternative Study. Menopause. 2003;10(2):147-53. PubMed PMID: 12627040.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study. AU - Burke,Gregory L, AU - Legault,Claudine, AU - Anthony,Mary, AU - Bland,Deirdre R, AU - Morgan,Timothy M, AU - Naughton,Michelle J, AU - Leggett,Kelly, AU - Washburn,Scott A, AU - Vitolins,Mara Z, PY - 2003/3/11/pubmed PY - 2003/6/21/medline PY - 2003/3/11/entrez SP - 147 EP - 53 JF - Menopause (New York, N.Y.) JO - Menopause VL - 10 IS - 2 N2 - OBJECTIVE: To investigate the efficacy of dietary soy proteins containing differing amounts of isoflavones on the number and severity of vasomotor symptoms (hot flashes and night sweats) in peri- and postmenopausal women. DESIGN: A double-masked, randomized, controlled, clinical trial was conducted. A total of 241 community-dwelling women reporting vasomotor symptoms at baseline were randomized into one of three groups. In all groups, participants consumed a daily supplement containing 25 g of soy protein and were randomly assigned to one of three groups: (a) isoflavone extracted soy protein (control), (b) soy protein with a medium dose of isoflavones (42 mg/day), or (c) soy protein with a higher dose of isoflavones (58 mg/day). The primary outcome measure in this trial was change in reported vasomotor symptoms. RESULTS: A reduction in the number and severity of vasomotor symptoms was observed in all three treatment groups. No significant differences in the number and severity of vasomotor symptoms were observed among the high isoflavone, middle isoflavone, or control groups. The lack of a between-treatment group effect was observed even after stratified by number of baseline symptoms and use of traditional hormone replacement therapy. CONCLUSIONS: These data suggest that soy protein containing 42 or 58 mg of isoflavones is no more effective than isoflavone-extracted soy protein for improving the number and severity of vasomotor symptoms in peri- and postmenopausal women. SN - 1072-3714 UR - https://www.unboundmedicine.com/medline/citation/12627040/Soy_protein_and_isoflavone_effects_on_vasomotor_symptoms_in_peri__and_postmenopausal_women:_the_Soy_Estrogen_Alternative_Study_ L2 - http://Insights.ovid.com/pubmed?pmid=12627040 DB - PRIME DP - Unbound Medicine ER -